Lunai Bioworks (NASDAQ:LNAI) Stock Price Down 6.3% – Should You Sell?

Lunai Bioworks Inc. (NASDAQ:LNAI)’s share price fell 6.3% on Tuesday . The stock traded as low as $0.6959 and last traded at $0.71. 185,926 shares were traded during mid-day trading, an increase of 14% from the average session volume of 163,261 shares. The stock had previously closed at $0.7575.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Wall Street Zen raised Lunai Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Lunai Bioworks Trading Down 6.3%

The business has a fifty day simple moving average of $1.00. The stock has a market capitalization of $16.64 million, a price-to-earnings ratio of -10.14 and a beta of 0.46.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.13 EPS for the quarter.

Institutional Investors Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC acquired a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to its most recent filing with the SEC. The firm acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent filing with the SEC. 71.41% of the stock is currently owned by hedge funds and other institutional investors.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.